

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

## Saphnelo

(anifrolumab-fnia)

PHYSICIAN INFORMATION			PATIENT INFORMATION				
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this				
Specialty:	Specialty: * DEA, NPI or TIN:		form are completed.*				
Office Contact Person:			* Patient Name:				
Office Phone:			* Cigna ID: * Date of Birth:				
Office Fax:			* Patient Street Address:				
Office Street Address:			City:	City: State: Zip:		Zip:	
City:	State:	Zip:	Patient Phone:			•	
Urgency: ☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)  Medication requested:							
☐ Saphnelo 300 mg/2 m☐ Other (please Specify	ICD10:						
Dose and Quantity: Duration			of therapy: J-Code:				
ls this a new start or a cor	ntinuation of t	herapy?	tart 🔲 cont	inued therapy	Start Date:		
(if continued therapy) Has your patient had a beneficial response to this drug? Examples of a response include reduction in flares, reduction in corticosteroid dose, decrease of anti-dsDNA titer, improvement in complement levels (C3, C4), or improvement in specific organ dysfunction (for example, musculoskeletal, blood, hematologic, vascular, others) ☐ Yes ☐ No (if no) Please provide clinical support for the continued use of Saphnelo.							
Where will this medic  ☐ US Bioservices ☐ Hospital Outpatient ☐ Retail pharmacy ☐ Other (please specify):		otained?		☐ Home Health☐ Physician's of claim form)			
Facility and/or doctor dispensing and administering medication:							
Facility Name: State: Address (City, State, Zip Code):			Tax ID#:				
Where will this drug b	oe adminis	tered?					
☐ Patient's Home ☐ Hospital Outpatient				☐ Physician's Off ☐ Other (please s			
<b>NOTE:</b> Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.							
ls this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):							

Urgency:					
☐ Standard					
☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the c health, or ability to regain maximum function)	ustomer's life,				
What is your patient's diagnosis?					
☐ Severe Active Central Nervous System Lupus ☐ Severe Active Lupus Nephritis ☐ Systemic Lupus Erythematosus (SLE) ☐ Other (please specify):					
Clinical Information: Does the patient have documentation of a positive autoantibody test (for example, anti-nuclear antibody [ANA] greated 1:80, anti-double-stranded DNA [anti-dsDNA] greater than or equal to 30 IU/ml, anti-Smith (anti-Sm) antibodies)?	er than or equal to				
ls the medication being used concurrently with at least ONE other standard therapy [for example, an antimalarial (for example, hydroxychloroquine), systemic corticosteroid (for example, prednisone), other immunosuppressants (for example, azathioprine, mycophenolate mofetil, methotrexate)]?					
(if no) Does the patient have intolerance to standard therapy due to a significant toxicity? ☐ Yes ☐ No					
ls Saphnelo being prescribed by, or in consultation with, a rheumatologist, clinical immunologist, nephrologist, neurologist?	ogist, or □ Yes □ No				
(if new start) Does your patient have depression or suicidality?	☐ Yes ☐ No				
(if new start) The covered alternative is brand Benlysta. If your patient has tried this drug, please provide drug strength, date(s) taken and for how long, and what the documented results were of taking this drug, including any intolerances or adverse reactions your patient experienced. If your patient has NOT tried this drug, please provide details why your patient can't try this alternative.					
Per the information provided above, which of the following is true for your patient in regards to the covered alternative, Benlysta?  The patient tried the alternative, but it didn't workwellenough.  The patient is able to try the alternative, but has not done so yet.  The patient tried the alternative, but they did not tolerate it.  The patient can't try the alternative because of a contraindication to this drug.  Other					
Besides the drug being requested, other biological drugs include Actemra, Avsola, Benlysta, Cimzia, Cosentyx, Enbrel (and its biosimilars), Entyvio, Humira (and its biosimilars), Ilumya, Inflectra, Kevzara, Kineret, Orencia, Remicade, Renflexis, Riabni, Rituxan (and its biosimilars), Siliq, Simponi/Simponi Aria, Skyrizi, Stelara, Taltz, Tremfya, and Truxima. Which of the following best describes your patient's situation?					
☐ The patient is NOT taking any other biological at this time, nor will they in the future. The requested drug is the only biological the patient is/will be using. ☐ The patient is currently on another biological, but this drug will be stopped and the requested drug will be started. ☐ The patient is currently on another biological, and the requested drug will be added. The patient may continue to take both drugs together. ☐ The patient is currently on BOTH the requested drug AND another biological. ☐ other/unknow n					
(if other/more than the requested drug) Please provide name of drug, dates taken and, if applicable, the clinical rationale for the combined use of the requested drug and another biologic to treat your patient's diagnosis.					
Additional Information:					

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or					
insurer its designees may perform a routine audit and request the me	dical information necessary to verify the accuracy of the				
information reported on this form.					
Prescriber Signature:	Date:				
Save Time! Submit Online at: <a href="https://www.covermymeds.com/main/prior-authorization-forms/cigna/">www.covermymeds.com/main/prior-authorization-forms/cigna/</a> or via SureScripts in your EHR.					

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v020123

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005